BRISTOL MYERS SQUIBB
๐ซ๐ทFrance
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT00254293
- Locations
- ๐บ๐ธ
Davita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธWinship Cancer Institute, Emory University, Atlanta, Georgia, United States
๐บ๐ธThe Arthritis Clinic & Carolina Bone & Joint, Charlotte, North Carolina, United States
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 520
- Registration Number
- NCT00252005
- Locations
- ๐ธ๐ช
Local Institution, Vastervik, Sweden
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 341
- Registration Number
- NCT00246987
- Locations
- ๐ฆ๐บ
Tasmania, Melbourne, Victoria, Australia
๐จ๐ณLocal Institution, Taichung, Taiwan
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 330
- Registration Number
- NCT00245388
- Locations
- ๐จ๐ฆ
Local Institution, Ottawa, Ontario, Canada
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1159
- Registration Number
- NCT00240370
- Locations
- ๐ต๐ท
Local Institution, Ponce, Puerto Rico
Dose Ranging Study With LT, Monotherapy, PPAR
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1260
- Registration Number
- NCT00240383
- Locations
- ๐ฌ๐ง
Local Institution, Glasgow, United Kingdom
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00207168
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00207051
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
MAD Refractory: Solid Tumor QD w/o Break
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00207012
- Locations
- ๐ช๐ธ
Local Institution, Barcelona, Spain
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00207025
- Locations
- ๐ง๐ช
Local Institution, Brussels, Belgium
ยฉ Copyright 2024. All Rights Reserved by MedPath